ReviewCancers2022

How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma.

Konstantinos Arvanitakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.